Background. The aim of this study was to evaluate the role of hypomagnesemia as a risk factor for the development of acute kidney injury (AKI) and non-recovery of renal function in critically ill patients. Methods. A cohort study was conducted by collecting data from March to June 2011 in 232 patients who were admitted into an intensive care unit (ICU). Magnesium serum levels were measured daily during ICU stay. Hypomagnesemia was defined as an episode of serum magnesium concentration of <0.70 mmol/L during ICU stay. The Risk, Injury, Failure, Loss and End-stage kidney disease (RIFLE) criteria were used to define AKI. Renal function recovery was defined as an absence of AKI by the RIFLE criteria over a 48-h period, or at ICU discharge, in the patients who developed AKI during ICU stay.
A B S T R AC T
Background. The aim of this study was to evaluate the role of hypomagnesemia as a risk factor for the development of acute kidney injury (AKI) and non-recovery of renal function in critically ill patients. Methods. A cohort study was conducted by collecting data from March to June 2011 in 232 patients who were admitted into an intensive care unit (ICU). Magnesium serum levels were measured daily during ICU stay. Hypomagnesemia was defined as an episode of serum magnesium concentration of <0.70 mmol/L during ICU stay. The Risk, Injury, Failure, Loss and End-stage kidney disease (RIFLE) criteria were used to define AKI. Renal function recovery was defined as an absence of AKI by the RIFLE criteria over a 48-h period, or at ICU discharge, in the patients who developed AKI during ICU stay.
Results. The presence of hypomagnesemia was similar in patients with or without AKI (47 and 62%, respectively, P = 0.36). The presence of hypomagnesemia was higher in patients who did not recover renal function when compared with patients who recovered renal function (70 versus 31%, P = 0.003). A multivariate analysis identified hypomagnesemia as an independent risk factor for non-recovery of renal function (P = 0.005). Patients with and without hypomagnesemia had similar mortality rates (P = 0.63). Conclusions. Hypomagnesemia was an independent risk factor for non-recovery of renal function in a cohort of critically ill AKI patients.
In animal experiments, hypomagnesemia decreases the glomerular filtration rate (GFR) and the renal blood flow (RBF), and enhances post-ischemic renal injury [2] . Conversely, administration of magnesium in an animal model of ischemic renal injury results in GFR and RBF increases [3] . However, there is only one report in the literature disclosing that hypomagnesemia was a risk factor for the non-recovery of renal function after an AKI episode in hospitalized patients with acquired immunodeficiency syndrome (AIDS) [4] .
Thus, the aim of the current study was to assess the role of hypomagnesemia in the development of AKI and the recovery of renal function after an AKI episode in critically ill patients.
M AT E R I A L S A N D M E T H O D S
A prospective cohort study was conducted, which included all the patients admitted into a 20-bed general ICU at a University Hospital (Hospital São José) in Criciúma, Brazil, from March to June, 2011. All procedures were approved by the local Ethics Committee and written informed consent was obtained from all patients or their relatives before inclusion in the study. Patients under 18 years of age, patients with serum creatinine (SCr) values greater than 3.5 mg/dL upon admission into the ICU (to avoid the inclusion of patients with advanced chronic renal disease) and patients with a stay in the ICU of <48 h were excluded from the study.
Demographic, clinical and laboratory data were collected, including age, gender, type of admission and comorbidities. The Acute Physiologic and Chronic Health Evaluation (APACHE) II score was estimated using data collected from the ICU admission (±1 h) and during the first 24 h of ICU stay. The sequential organ failure assessment (SOFA) score was also calculated on the first day of ICU admission. Major comorbidities were assessed revising patient medical charts. Sepsis was diagnosed according to previously published definitions [5] .
Hypomagnesemia was defined as any measure of serum magnesium <0.70 mmol/L [6] during ICU stay. Total serum magnesium levels were determined daily until ICU discharge with a colorimetric method using the VITROS 250 Chemistry Analyzer (Johnson & Johnson Co., USA). Magnesium levels were used to derive four variables: the presence of hypomagnesemia, lower magnesium level, mean magnesium level and severity of hypomagnesemia (≤0.41 mmol/L as severe, 0.41-0.53 mmol/L as moderate and 0.54-0.69 mmol/L as mild).
AKI was diagnosed by the Risk, Injury, Failure, Loss and End-stage kidney disease (RIFLE) criteria [7] . RIFLE is graded in five increasing levels of severity. The first stage, Risk is defined as an abrupt (within 1-7 days) and sustained (>24 h) SCr increase to ≥1.5 times the reference SCr or a urine output <0.5 mL/kg/h for 6 h. The second stage is defined as a SCr increase to two times the reference SCr or a urine output <0.5 mL/kg/h for 12 h. The third stage, Failure is defined as a SCr increase to three times the reference SCr or when reference SCr ≥4 mg/dL as an acute increase >0.5 mg/dL in the reference SCr or as a urine output <0.3 mL/kg/ h for 24 h or anuria for 12 h. Loss is defined as complete loss of kidney function for >4 weeks, and end-stage kidney disease as the complete or almost complete failure of the kidneys for >3 months.
The primary study outcomes were the prevalence of AKI and renal function recovery, defined as at least 48 h without AKI in the ICU or at ICU discharge according RIFLE criteria, in patients who developed AKI during ICU stay. Secondary outcome was mortality. Both primary and secondary outcomes were defined until ICU discharge or after a maximum period of up to 28 days in the ICU.
Magnesium supplementation was performed by the ICU staff without interference from the study investigators, following institutional guidelines. This guideline indicates magnesium supplementation in the cases of severe or symptomatic hypomagnesemia, or hypomagnesemia in the setting of hypokalemia.
Clinical data were analyzed using SPSS software (Statistical Package for the Social Sciences, Version 15.0). Standard descriptive statistics were used to describe the study population. Continuous variables were reported as the mean ± SD or the median (25-75% interquartile range), depending on the variable distribution, as determined by analysis with the Kolmogorov-Smirnov test. To identify factors associated with outcomes, a univariate analysis was performed on all collected variables using a χ 2 test for categorical variables, or a Student t-test or Mann-Whitney U-test, as appropriate, for continuous variables. Variables yielding P < 0.15 in the univariate analysis or considered clinically relevant were entered into a binary logistic regression model that included hypomagnesemia, sepsis, age, APACHE II score and the RIFLE score to estimate the independent association of each covariate with the dependent variable. The Hosmer-Lemeshow goodness-of-fit test was used to evaluate the agreement between the observed and expected number of patients who recovered renal function. The area under receiver operating characteristic curve (AUROC) was used to evaluate the ability of magnesium levels to predict the recovery from AKI. The relation between primary and secondary outcomes and hypomagnesemia were analyzed by the Kaplan-Meier curves followed by the log-rank test. A two-tailed test was used to determine statistical significance (P < 0.05).
R E S U LT S
A total of 355 patients admitted into the ICU were screened, and 123 of these patients were excluded from the study for the following reasons: 83 patients remained in the ICU for <8 h, 32 patients had ICU admission SCr values ≥3.5 mg/dL and 8 patients were <18 years of age. Thus, 232 patients were included in the study (Figure 1) . Table 1 summarizes the general characteristics in patients with and without AKI. Patients with AKI presented more frequently with sepsis (P = 0.007), had a higher APACHE II score (P = 0.007), were admitted due to medical reasons (P = 0.005), and needed vasopressors (P = 0.03). There was a significant difference among the mortality rates of patients
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with and without AKI (32.2 versus 10.5%, respectively, P < 0.0001). Renal replacement therapy (RRT) was needed in 35 (30%) of AKI patients, and 8 remained on RRT at the end of study. All patients received daily intermittent hemodialysis or extended RRT. The prevalence of hypomagnesemia was 63% (146 of 232). Ninety-seven of the patients who were admitted into the ICU already presented with hypomagnesemia, with a mean hypomagnesemia duration during ICU stay of 3.1 ± 2.9 days. Among the patients with hypomagnesemia, 75 developed AKI, but 20 of them developed AKI before the occurrence of hypomagnesemia, and were thus excluded in the analyses related to AKI. The prevalence of hypomagnesemia was similar in the groups with and without AKI (47 versus 62%, P = 0.36), and the presence or absence of hypomagnesemia was not associated with AKI (Figure 2A ). There was no significant association between serum magnesium levels or the presence of hypomagnesemia and RIFLE stages (P = 0.10 and P = 0.15, data not shown). Table 2 summarizes the general characteristics of the patients who recovered and whose did not recover renal function. The prevalence of hypomagnesemia was significantly higher in the patients who did not recover renal function compared with those who recovered the renal function (70 versus 31%, respectively, P = 0.003), and the presence or absence of hypomagnesemia was associated with recovery of renal function ( Figure 2B ). Neither the lower magnesium level or the mean magnesium levels during ICU stay were significantly different in the patients that recovered and whose did not recover the renal function (Table 2) . Using a ROC curve analyses the discriminatory power of the lower magnesium levels and the mean magnesium levels was weak (AUROC = 0.542 and 0.544). Even when hypomagnesemia was stratified as mild, moderate or severe we did not find any significant difference in the renal function recovery between the two magnesium levels groups ( Table 2 ). The RIFLE score correlated significantly with the renal function recovery. Patients in the R category recovered renal function more frequently than those in the I or F categories (P = 0.001). In the multivariate analyses, hypomagnesemia was a significant risk factor for non-recovery of renal function (Table 3) . ICU mortality was similar in patients with and without hypomagnesemia ( Figure 2C ).
D I S C U S S I O N
This study demonstrated that hypomagnesemia was an independent risk factor for the non-recovery of renal function after an AKI episode in this cohort of critically ill patients. There is only one previous clinical study that demonstrated a significant difference in renal function recovery between AIDS patients with and without hypomagnesemia [4] .
Several possible hypotheses can be formulated to try to explain the association between magnesium deficiency and impaired renal function recovery after AKI. Currently, the main causes for AKI in critically ill patients are ischemia and 
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H y p o m a g n e s e m i a a n d A K I exposure to nephrotoxic drugs [8] . Magnesium competes with the calcium transport systems in the cell membrane, which diminishes the intracellular calcium concentrations, resulting in the relaxation of smooth muscle cells [9] . In mesangial cells in culture, magnesium inhibits the contraction induced by cyclosporine and angiotensin II [10] , while hypomagnesemia potentiates the post-ischemic renal injury in rats [2] . In models of nephrotoxic AKI, magnesium supplementation was found to have beneficial effects [11] . In addition, hypomagnesemia decreases the GFR and the RBF in zidovudine-treated rats [12] . The renal vasodilatation induced by magnesium can be attributed to the mechanisms identified in other vascular beds, in which magnesium acts by stimulating the release of nitric oxide (NO) [13] . Magnesium administration induces a peripheral ( predominantly arteriolar) vasodilator effect, not only via an endotheliumdependent release of NO, but also directly via its ability to induce endothelium-independent vasodilatation by acting as a calcium channel antagonist [13] . In addition to its vasodilator effects, infusion of magnesium is associated with microcirculatory effects, such as an increase in red blood cell deformability, a reduction of platelet aggregation, anti- (13) 7 (10) 8 (17) F, n (%) 31 (26) 11 (15) 20 (43) Hypomagnesemia, n (%) 55 (47) inflammatory effects and maintenance of endothelial integrity [14] . Low magnesium levels are associated with higher incidence of cardiovascular disease both in chronic kidney disease (CKD) and non-CKD patients [15, 16] . Holzmacher et al. [17] demonstrated that low magnesium levels were associated with a decline in the kidney allograft function and an increased rate of graft loss. Low magnesium levels are also associated with the mortality in end-stage renal disease [18] . The prevalence of hypomagnesemia among the 232 ICU patients assessed in this study was high, reaching 63%. In fact, hypomagnesemia is one of the most common electrolyte disturbances found in hospitalized patients, especially in the critically ill population. The reported prevalence of hypomagnesemia (assessed by measuring total serum magnesium concentrations) varies widely from one study to another, ranging from 11 to 65%, and the effects of hypomagnesemia on morbidity and mortality remain controversial [19] . In the present study, we did not find any significant effect of hypomagnesemia on patient mortality. In contrast, Rubeiz et al. [20] reported nearly doubled mortality rates in hypomagnesemic versus normomagnesemic patients (46 versus 25%, respectively), a result similar to that observed by Safavi and Honarmand [21] . However, Guerin et al. [22] did not find any differences in ICU mortality rates between hypomagnesemic and normomagnesemic patients (18 versus 17%, respectively). Similarly, Chernow et al. [6] reported no differences in mortality between hypomagnesemic and normomagnesemic patients (13 versus 11%, respectively). Studies that found a relation between hypomagnesemia and mortality usually presented higher mortality rates compared with those studies that did not demonstrate such a relation. Thus, it is possible that the pathophysiologic alterations related to hypomagnesemia and mortality are essentially relevant to more severe critically ill patients. On the other hand, in these patients hypomagnesemia might reflect some confounder in the data analyses, which was more prevalent in the more severely ill patients group. The higher mortality rates found in some studies among the hypomagnesemic patients might also be related to a greater frequency of other electrolyte abnormalities (especially hypokalemia) and cardiac arrhythmias, and to a strong association of hypomagnesemia with sepsis and septic shock, which are the most common causes of death in the ICU patients [6] .
The present study has some limitations. This is a singlecenter study, thus the results presented here can be biased due to some non-identified center characteristic. Since AKI and recovery from AKI are multifactorial in origin, several confounders for the association between magnesium levels and the outcomes, which were assessed in the analyses, might interfere in the results. We cannot find a clear 'dose-response' effect of magnesium and recovery from AKI, but the majority of our patients developed mild hypomagnesemia and this might influence the observed results.
In conclusion, hypomagnesemia was identified as an independent risk factor for non-recovery of renal function among AKI patients in the ICU. 
